ALT

Altimmune, Inc.

Healthcare
Biotechnology
$636M market cap

Forecast run · Sep 14, 2026Upside rank 1053 of 3,136

Model Signal

ForecastQ Daily Probabilities

44.0%

46.9%

20.1%

Analyst Consensus

Recommendation2.20/5 Buy

Last price$3.27

Price target$6.25

Implied move+91.1%

Analysts15

ForecastQ Portfolios

ALT is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.